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The relation between the metabolic syndrome
(MetS) and resting heart rate (rHR) in patients
with diabetes and coronary artery disease is
unknown. The authors examined the
cross-sectional association at baseline between
components of the MetS and rHR and between
rHR and left ventricular ejection fraction in the
population from the Bypass Angioplasty
Revascularization Investigation 2 Diabetes (BARI
2D) randomized clinical trial. The mean rHR in
the MetS group was significantly higher than in
those without (68.412.3 vs 65.611.8 beats per
min, P=.0017). The rHR was higher (P<.001
for trend) with increasing number of components
for MetS. Linear regression analyses demonstrated
that as compared to individuals without MetS,
rHR was significantly higher in participants with
MetS (regression coefficient, 2.9; P=.0015). In
patients with type 2 diabetes and coronary artery
disease, the presence of higher rHR is associated
with increasing number of criteria of MetS and
the presence of ventricular dysfunction. Prev
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The importance of resting heart rate (rHR) asa prognostic factor and potential therapeutic
target is not yet generally accepted.1 A large num-
ber of studies have shown that high rHR is a pre-
dictor of increased morbidity and mortality
among people with coronary artery disease
(CAD)1–3 and diabetes.4 Higher rHR is also asso-
ciated with incident diabetes.5
Heart rate has shown to be related to insulin
sensitivity and insulin secretion,6 while elevated
heart rate has been shown to precede the develop-
ment of the metabolic syndrome (MetS).7 MetS is
associated with autonomic dysfunction8; thus, ele-
vated rHR may be a marker of absolute or relative
sympathetic overactivity.
A recent meta-analysis showed that MetS is associ-
ated with increased risk of cardiovascular events and
death.9 Another study showed that high rHR clusters
with other cardiovascular risk factors, such as hyper-
tension, diabetes, and hypertriglyceridemia.10 How-
ever, the relation between MetS and rHR in patients
with diabetes and CAD is unknown, and there
remains a need to identify interventions targeting
rHR or the mechanisms behind it.
Bypass Angioplasty Revascularization Investiga-
tion 2 Diabetes (BARI 2D) is a National Institutes
of Health–sponsored randomized clinical trial evalu-
ating treatment for patients with type 2 diabetes
and angiographically documented stable CAD.11
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We examined the association between components
of the MetS and rHR in this patient population at
baseline. We also evaluated the relationship between
rHR and left ventricular ejection fraction (LVEF).
METHODS
The study design, including specific inclusion and
exclusion criteria for BARI 2D participants, is sum-
marized elsewhere.11 MetS was defined by the crite-
ria of the National Cholesterol Education Program’s
Adult Treatment Panel III (NCEP ATP III).12 Since
all patients had type 2 diabetes, MetS was defined
as presence of 2 of the following components: (1)
waist circumference >102 cm in men and >88 cm
in women; (2) triglycerides 150 mg ⁄dL; (3) high-
density lipoprotein cholesterol <40 mg ⁄dL in men
and <50 mg ⁄dL in women; and (4) blood pressure
130 ⁄ 85 mm Hg or being treated for hyperten-
sion.
Heart rate was evaluated from standard 12-lead
resting electrocardiography recorded with the patient
supine and resting. Analyses were performed accord-
ing to the Minnesota code.13 We excluded all
patients with history of atrial fibrillation. All electro-
cardiographic results were evaluated by an experi-
enced cardiologist who was masked to the diagnosis
and outcome of the individual patients. LVEF was
measured (n=2117) at each of the clinical sites with
the modality of choice of that site. The modes were
angiography (69%), perfusion scanning (20%), trans-
thoracic echocardiography (6%), and other (4%).
Baseline characteristics were compared across
heart rate quartiles using chi-square tests of general
association for proportions. Continuous data were
compared across heart rate quartiles using analysis
of variance F-tests if normally distributed and the
Kruskal-Wallis test if the data were non-normal.
Linear trends in proportions of the baseline charac-
teristics across heart rate quartiles were tested using
the Cochran-Mantel-Haenszel chi-square. Unad-
justed linear models of rHR were used to obtain
estimates of average change in rHR due to higher
number of MetS components. Increasing trends in
rHR by number of MetS risk factors were detected
by adding linear contrasts to each of the unadjusted
regression models. Adjusted models including age,
sex, ethnicity, b-blocker use, calcium channel
blocker use, exercise, smoking status, and prior
revascularization were used to determine the inde-
pendent relationship of MetS with rHR. Similar
unadjusted and adjusted linear models were also
used to determine the relationship between rHR
and LVEF.
In order to determine which MetS component
accounted for the most variability in rHR, a refer-
ence model of rHR that included age, sex, ethnicity,
b-blocker use, calcium channel blocker use, exercise,
smoking status, and prior revascularization was first
constructed and the R2 noted. Then 4 separate
models were constructed, each including all the
covariates from the reference model and one of the
components of MetS. The difference between the R2
of the reference model and the R2 from each of the
component models was calculated. These 4 differ-
ences were then compared to determine which MetS
component explained the most variability in rHR.
RESULTS
We evaluated 2214 BARI 2D participants with
complete baseline records including measurement of
the rHR. The mean rHR was 68.2 (range, 36–110)
beats per min (bpm). The participants in the
increasing rHR quartile had significantly (P<.001
for trend) greater body mass index and higher
hemoglobin A1c (HbA1c) value and were more likely
to be female and smokers (Table I).
In BARI 2D, of the 2174 participants who had all
the variables required for MetS criteria, 92.4% met
the described definition of MetS at baseline. The
mean rHR in the MetS group was significantly
higher than in those without (68.412.3 vs 65.6
11.8 bpm, P=.0017). Adjusted linear regression anal-
yses demonstrated that as compared to individuals
without MetS, rHR was significantly higher in partic-
ipants with MetS (regression coefficient, 2.9; P=
.0015). The rHR was higher (P<.001 for trend) with
increasing number of components for MetS. This
trend was also observed in an adjusted linear model
(Table IIB). Table IIC shows the amount of variation
of rHR explained by each of the individual compo-
nents of MetS. The reference model for rHR
included age, sex, ethnicity, smoking status, and prior
revascularization status and had an R2 of 0.0279;
after addition of waist circumference, the R2
increased to 0.0413. Based on the change in R2 from
each of the 4 MetS component models to the refer-
ence model, waist circumference explained the most
variation in rHR. The coefficient from the regression
model for waist circumference category was 3.5. In
the adjusted model, HbA1c accounted for about
1.8% of the variability in heart rate.
Table III shows that the rHR was significantly
higher in participants with lower LVEF categories
(P=.007 for trend). Compared to participants with
LVEFs of 55%, participants with LVEFs <35%
had adjusted regression coefficient of 4.3 (P<.001)
(Table IIIB). We also observed that 1.1% of the
variation in heart rate was explained by the MetS
factors after accounting for LVEF.
DISCUSSION
In this cross-sectional analysis, we demonstrate that
in patients with type 2 diabetes and confirmed
CAD, the presence of MetS is associated with
higher rHR, with waist circumference contributing
the most to this relationship. We also showed that
there was a graded increase in rHR with decreasing
LVEF.
A recent study14 has shown that heart rate vari-
ability (HRV) indices in the group with MetS were
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significantly lower than those in the group without
MetS (P<.05). Furthermore, a significant negative
correlation was found between all components of
MetS and the HRV indices; additionally, as the num-
ber of MetS components increased, the HRV indices
gradually decreased. Data regarding the relationship
between heart rate and MetS are, however, lacking.
Ioune and associates10 showed that the odds of hav-
ing increased heart rate (>77 bpm) increased with
increasing number of risk factors such as hyperten-
sion, diabetes mellitus, and hypertriglyceridemia.
Increased heart rate is a marker of lower parasym-
pathetic tone or higher sympathetic activity,15 and
higher sympathetic tone can cause insulin resistance
by adrenergic stimulation.16 Conversely, insulin resis-
tance and hyperinsulinemia can cause sympathetic
overactivity, leading to cardiac autonomic dysfunc-
tion.17,18 In our study, patients with more MetS risk
factors had higher rHR, and such risk factors have
been hypothesized to be also related to sympathetic
overactivity.8,19,20 A recent study showed that
sympathetic nerve traffic was significantly greater in
persons with MetS than in controls.21 Increased
heart rate due to an autonomic dysfunction with
absolute or relative sympathetic overactivity may be
one way MetS imparts higher risk for cardiovascular
disease.
We showed that out of all the components of
MetS, waist circumference was most correlated to
rHR. A recent study22 showed that waist circumfer-
ence was a better correlate of HRV parameters than
body mass index and that obesity was related
to sympathovagal imbalance characterized by
depressed parasympathetic tone and increased sym-
pathetic activity. Moreover, several associations
between HRV parameters and adipokines were
observed, indicating a possible link between adipo-
kines and disturbances of the autonomic nervous
system.
We also showed that higher rHR was associated
with worsening left ventricular dysfunction. It has
been reported that in patients with ischemic heart















Age at study entry, y
(mean, SD)
62.3, 8.9 63.4, 8.6 62.4, 8.9 61.9, 8.5 61.2, 9.4 .0014
Female 29.8% 24.3% 29.9% 30.4% 35.0% .0003
Ethnicity
Black nH 16.8% 14.8% 15.7% 15.9% 20.7% .04
Hispanic 13.0% 14.8% 10.8% 12.1% 14.1%
White nH 65.4% 64.2% 68.2% 68.1% 61.4%
Asian ⁄ other nH 4.8% 6.2% 5.2% 3.8% 3.8%
Exercise regularly 25.6% 28.4% 25.1% 21.0% 27.9% .018
Current smoker 12.5% 9.5% 10.7% 15.0% 15.0% .005
BMI, kg ⁄ m2 (mean, SD) 31.7, 5.9 31.1, 5.6 31.2, 5.7 31.9, 5.7 32.7, 6.4 <.001
Waist circumference (>102 cm
men, >88 cm women)
74.2% 68.2% 79.4% 76.9% 82.4% <.001
Lipid values, mg ⁄ dL (mean, SD)
Total cholesterol 169.6, 40.5 165.1, 38.0 167.5, 38.3 169.8, 39.3 166.5, 45.4 <.001
LDL cholesterol 96.5, 33.2 94.6, 31.5 95.1, 32.5 96.1. 34,1 100.5, 34.6 .017
HDL cholesterol 38.3, 10.3 38.2, 13.8 38.4, 10.2 38.2, 10.7 38.3, 10.4 <.99
Triglycerides (mean, median) 179.8, 149 163.1, 139 176.1, 147 186.0, 158 194.9, 155 .007
Blood pressure, mm Hg (mean, SD)
Systolic 131.8, 20.1 132.8, 21.2 131.6, 19.8 132.0, 20.3 130.7, 19.2 .35
Diastolic 74.7, 11.2 73.9, 11.1 74.5, 11.2 74.5, 10.9 75.8, 11.7 .026
History of treated hypertension, % 82.5 82.9 82.0 83.1 81.9 .94
Hemoglobin A1c, % (mean, SD) 7.67, 1.61 7.36, 1.53 7.58, 1.53 7.76, 1.57 8.02, 1.75 <.001
Diabetes duration, y (mean, SD) 10.4, 8.6 9.7, 8.7 10.4, 8.5 10.7, 8.4 10.7, 8.9 .14
Insulin use 27.9% 20.7% 25.2% 32.4% 33.5% <.001
b-Blocker use 73.1% 83.1% 80.4% 69.1% 59.4% <.001
Prior CABG 6.1% 5.9% 7.9% 5.1% 5.9% .26
Prior PCI 19.8% 21.3% 21.5% 18.8% 17.4% .25
Abbreviations: BMI, body mass index; bpm, beats per min; CABG, coronary artery bypass graft; HDL, high-density
lipoprotein; HR, heart rate; LDL, low-density lipoprotein; nH, non-Hispanic; PCI, percutaneous coronary intervention;
SD, standard deviation.
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disease, increased heart rate reflects a degree of left
ventricular dysfunction23 and that an increased rHR
could additionally worsen cardiovascular prognosis
due to increased shear stress24 and progression of
atherosclerosis.3
The limitations of our study include the cross-
sectional nature of the analyses; thus, no causation
can be established. We did not measure indices for
HRV. Although we controlled for exercise in the
multiavariable analyses, we did not measure cardio-
respiratory fitness in the trial. Patients with MetS
were more likely to be receiving b-blockers (74% vs
66%, P<0.01). Accordingly, we adjusted the multi-
variable model by baseline b-blocker use. However,
Table II. Relationship of Metabolic Syndrome (MetS) and Presence of Number and Type of Its Components and Heart Rate










MetS (2 RFs) (n=1973) 68.412.3 2.9 .0017 2.9 .0015
No MetS (0 or 1 RF) (n=201) 65.611.8 .0017
B. ACCORDING TO PRESENCE OF












0 or 1 (n=201) 65.611.8 <.001 0 or 1 <.001 – <.001
2 (n=510) 66.812.0 1.3 1.3
3 (n=751) 68.512.4 2.9 2.9
4 (n=712) 69.512.3 <.001 4.0 4.3
C. ACCORDING TO PRESENCE OF




REGRESSION MODEL P VALUE – –
Reference modelb 0.0279 – –
Waist circumference >100 cm for
men and >88 cm for women
0.0413 .0134 3.5 <.0001 – –
Triglycerides >150 mg ⁄ dL 0.0294 .0015 1.16 .03 – –
HDL cholesterol <40 mg ⁄ dL for
men and <50 mg ⁄ dL for women
0.0279 .0 0.66 .27 – –
Blood pressure >130 ⁄ 85 mm Hg 0.0275 ).0004 0.48 .53 – –
Abbreviations: HDL, high-density lipoprotein cholesterol; RF, risk factor; SD, standard deviation. aAdjusted for age, sex,
race ⁄ ethnicity, use of b-blockers, use of calcium channel blockers, exercise, smoking, and prior revascularization. bReference
model of heart rate includes age, sex, race ⁄ ethnicity, current smoking, and prior revascularization.
Table III. Relationship Between Left Ventricular Ejection Fraction (LVEF) and Heart Rate











LVEF <50% (n=358) 69.713.1 1.7 .017 1.8 .009
LVEF 50% (n=1785) 68.012.2 .017













<35% (n=61) 72.113.4 .007 4.30 .007 4.5 .004
35%–45% (n=153) 69.513.2 1.70 1.8
45%–55% (n=423) 68.812.4 0.99 1.4
55% (n=1457) 67.812.2 1.00 – 1 –
Abbreviation: SD, standard deviation. aAdjusted for age, sex, race ⁄ ethnicity, use of b-blockers, use of calcium channel blockers,
exercise, smoking, and prior revascularization.
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this makes our results even more interesting because
a lower heart rate is expected with b-blocker use.
Since all participants had diabetes and coronary
heart disease, our analyses can not be extrapolated
to people with MetS but without diabetes or CAD.
In summary, presence of MetS is associated with
higher rHR in patients with type 2 diabetes and
CAD and may be one way MetS confers additional
cardiovascular risk.
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